Anti-PD-L1 Lead-in Before MAPKi Combination Maximizes Anti-Tumor Efficacy and Immunity [scRNAseq and scTCR-seq]

⚠︎Low quality — median 92 genes per cell. Datasets below 100 genes/cell may not produce meaningful analysis results.